Next Article in Journal
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)
Previous Article in Journal
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine
Article Menu

Export Article

Open AccessArticle
Vaccines 2015, 3(3), 503-518;

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus

School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA
Author to whom correspondence should be addressed.
Academic Editors: Annelies Wilder-Smith and Eng Eong Ooi
Received: 12 May 2015 / Revised: 18 June 2015 / Accepted: 30 June 2015 / Published: 3 July 2015
(This article belongs to the Special Issue Dengue Vaccines)
Full-Text   |   PDF [230 KB, uploaded 3 July 2015]   |  


Vaccines against dengue virus (DV) are commercially nonexistent. A subunit vaccination strategy may be of value, especially if a safe viral vector acts as biologically active adjuvant. In this paper, we focus on an immunoglobulin-like, independently folded domain III (DIII) from DV 2 envelope protein (E), which contains epitopes that elicits highly specific neutralizing antibodies. We modified the hepatitis B small surface antigen (HBsAg, S) in order to display DV 2 DIII on a virus-like particle (VLP), thus generating the hybrid antigen DIII-S. Two varieties of measles virus (MV) vectors were developed to express DIII-S. The first expresses the hybrid antigen from an additional transcription unit (ATU) and the second additionally expresses HBsAg from a separate ATU. We found that this second MV vectoring the hybrid VLPs displaying DIII-S on an unmodified HBsAg scaffold were immunogenic in MV-susceptible mice (HuCD46Ge-IFNarko), eliciting robust neutralizing responses (averages) against MV (1:1280 NT90), hepatitis B virus (787 mIU/mL), and DV2 (1:160 NT50) in all of the tested animals. Conversely, the MV vector expressing only DIII-S induced immunity against MV alone. In summary, DV2 neutralizing responses can be generated by displaying E DIII on a scaffold of HBsAg-based VLPs, vectored by MV. View Full-Text
Keywords: measles vectors; HBsAg subviral particles; dengue vaccine platform measles vectors; HBsAg subviral particles; dengue vaccine platform

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Harahap-Carrillo, I.S.; Ceballos-Olvera, I.; Valle, J.R.-D. Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus. Vaccines 2015, 3, 503-518.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top